相似文献
1
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents.
Open Forum Infect Dis. 2016 Oct 7;3(4):ofw189. doi: 10.1093/ofid/ofw189. eCollection 2016 Oct.
2
Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.02092-16. Print 2017 May 1.
3
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
J Virol. 2018 Apr 13;92(9). doi: 10.1128/JVI.01931-17. Print 2018 May 1.
4
A Critical Review of the Evidence Concerning the HIV Latency Reversing Effect of Disulfiram, the Possible Explanations for Its Inability to Reduce the Size of the Latent Reservoir In Vivo, and the Caveats Associated with Its Use in Practice.
AIDS Res Treat. 2017;2017:8239428. doi: 10.1155/2017/8239428. Epub 2017 Mar 30.
5
Antibody-Mediated CD4 Depletion Induces Homeostatic CD4 T Cell Proliferation without Detectable Virus Reactivation in Antiretroviral Therapy-Treated Simian Immunodeficiency Virus-Infected Macaques.
J Virol. 2018 Oct 29;92(22). doi: 10.1128/JVI.01235-18. Print 2018 Nov 15.
6
The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
J Virol. 2018 Jun 13;92(13). doi: 10.1128/JVI.02225-17. Print 2018 Jul 1.
7
Reversal of Latency as Part of a Cure for HIV-1.
Trends Microbiol. 2016 Feb;24(2):90-97. doi: 10.1016/j.tim.2015.11.003. Epub 2015 Dec 11.
8
Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
mBio. 2018 Nov 13;9(6):e02158-18. doi: 10.1128/mBio.02158-18.
9
Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
J Virol. 2019 Aug 28;93(18). doi: 10.1128/JVI.00495-19. Print 2019 Sep 15.
10
Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.
J Infect Dis. 2017 Mar 15;215(suppl_3):S111-S118. doi: 10.1093/infdis/jiw618.
引用本文的文献
1
The intestinal interferon system and specialized enterocytes as putative drivers of HIV latency.
Front Immunol. 2025 May 14;16:1589752. doi: 10.3389/fimmu.2025.1589752. eCollection 2025.
2
BRD9 functions as an HIV-1 latency regulatory factor.
Proc Natl Acad Sci U S A. 2025 May 27;122(21):e2418467122. doi: 10.1073/pnas.2418467122. Epub 2025 May 22.
3
Mitotic deacetylase complex (MiDAC) recognizes the HIV-1 core promoter to control activated viral gene expression.
PLoS Pathog. 2024 May 23;20(5):e1011821. doi: 10.1371/journal.ppat.1011821. eCollection 2024 May.
4
Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure.
J Transl Med. 2023 Nov 7;21(1):791. doi: 10.1186/s12967-023-04669-4.
5
TLR7 Agonist GS-9620 Combined with Nicotinamide Generate Viral Reactivation in Seronegative SHIV-Infected Rhesus Monkeys.
Biomedicines. 2023 Jun 14;11(6):1707. doi: 10.3390/biomedicines11061707.
6
PARP1 Might Substitute HSF1 to Reactivate Latent HIV-1 by Binding to Heat Shock Element.
Cells. 2022 Jul 29;11(15):2331. doi: 10.3390/cells11152331.
7
HIV cure strategies: which ones are appropriate for Africa?
Cell Mol Life Sci. 2022 Jul 6;79(8):400. doi: 10.1007/s00018-022-04421-z.
8
Comprehensive Comparison of Novel Bovine Leukemia Virus (BLV) Integration Sites between B-Cell Lymphoma Lines BLSC-KU1 and BLSC-KU17 Using the Viral DNA Capture High-Throughput Sequencing Method.
Viruses. 2022 May 7;14(5):995. doi: 10.3390/v14050995.
9
Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment.
Pharmaceuticals (Basel). 2022 Mar 10;15(3):338. doi: 10.3390/ph15030338.
10
Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice.
Diagnostics (Basel). 2021 Dec 24;12(1):39. doi: 10.3390/diagnostics12010039.
本文引用的文献
1
Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.
Science. 2016 May 20;352(6288):1001-4. doi: 10.1126/science.aaf1279. Epub 2016 May 5.
2
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
Science. 2016 May 20;352(6288):997-1001. doi: 10.1126/science.aaf0972. Epub 2016 May 5.
3
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
PLoS Pathog. 2016 Apr 15;12(4):e1005545. doi: 10.1371/journal.ppat.1005545. eCollection 2016 Apr.
4
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.
AIDS. 2016 Jun 1;30(9):1385-92. doi: 10.1097/QAD.0000000000001064.
5
A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
J Virol. 2016 Apr 14;90(9):4441-4453. doi: 10.1128/JVI.00222-16. Print 2016 May.
6
Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.
Vaccine. 2016 Feb 24;34(9):1215-24. doi: 10.1016/j.vaccine.2015.12.021. Epub 2016 Jan 16.
7
Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8. doi: 10.1097/QAI.0000000000000926.
8
Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1560-72. doi: 10.1128/AAC.02625-15.
9
Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial.
AIDS. 2016 Jan;30(2):221-30. doi: 10.1097/QAD.0000000000000894.
10
Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.
EMBO Mol Med. 2016 Feb 1;8(2):117-38. doi: 10.15252/emmm.201505557.
Zotero 插件